<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158506</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0105</org_study_id>
    <nct_id>NCT03158506</nct_id>
  </id_info>
  <brief_title>Human Mass Balance Study of HMS5552 in Healthy Subjects</brief_title>
  <official_title>An Open-Label, Single Center Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of 50 mg (90 uCi) [14C]-HMS5552 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single center, 1-period study in healthy adult male subjects to assess
      absorption, metabolism, and excretion of HMS5552 after a single oral administration of 50 mg
      (90 Î¼Ci) of [14C]-HMS5552.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity in blood, plasma urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in blood, plasma urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in blood, plasma urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Time to reach Cmax (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in blood, plasma urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Total radioactivity in urine and faeces at each time interval and cumulative radioactivity (mass balance)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of HMS5552 and its metabolites in plasma, urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Adverse events; Laboratory parameters; Vital signs, clinical signs and symptoms and physical examination, including changes from baseline; ECG evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of HMS5552 and its metabolites in plasma, urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of HMS5552 and its metabolites in plasma, urine and feces</measure>
    <time_frame>0-168 hours</time_frame>
    <description>Time to reach Cmax (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>[C14]-labelled HMS5552</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>[14C]-labelled HMS5552</description>
    <arm_group_label>[C14]-labelled HMS5552</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, male 19-55 years of age

          -  Weight at least 50 kg, and BMI within the range of 18-30 kg/m2

          -  Written informed consent must be obtained before any assessment is performed

        Exclusion Criteria:

          -  History or presence of clinically significant medical, surgical or psychiatric
             condition or disease in the opinion of the Investigator or designee which might
             significantly alter the absorption, distribution, metabolism and excretion of drugs.

          -  History or presence of alcoholism or drug abuse.

          -  Smoker.

          -  Abnormal bowel habits.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hua Medicine (shanghai) Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

